Trius patent allowed for tedizolid-daptomycin bacteremia combo
This article was originally published in Scrip
Executive Summary
On the eve of Trius Therapeutics' pursuit of US FDA approval for the antibiotic tedizolid phosphate, the San Diego-based company continues to expand the potential market for its drug candidate with patent protection for a tedizolid and daptomycin combination.